Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 368,832,320
  • Shares Outstanding, K 2,686,520
  • Annual Sales, $ 71,890 M
  • Annual Income, $ 16,540 M
  • 36-Month Beta 0.82
  • Price/Sales 5.17
  • Price/Cash Flow 16.71
  • Price/Book 5.02

Price Performance

See More
Period Period Low Period High Performance
1-Month
136.60 +0.51%
on 11/22/17
144.35 -4.89%
on 10/23/17
-5.11 (-3.59%)
since 10/20/17
3-Month
129.05 +6.39%
on 09/29/17
144.35 -4.89%
on 10/23/17
+2.59 (+1.92%)
since 08/22/17
52-Week
109.32 +25.59%
on 12/07/16
144.35 -4.89%
on 10/23/17
+24.55 (+21.78%)
since 11/22/16

Most Recent Stories

More News
JP Morgan Launches US Dividend ETF

JP Morgan rolls out multi-cap US Dividend ETF.

HFC : 44.39 (-0.89%)
JDIV : 25.11 (unch)
DVY : 95.61 (-0.01%)
JNJ : 137.29 (-0.76%)
SDY : 93.59 (+0.05%)
DLR : 117.21 (-0.90%)
MCD : 169.05 (+0.45%)
NNN : 42.55 (-0.26%)
MSFT : 83.11 (-0.73%)
LMT : 314.87 (-0.65%)
T : 34.87 (+1.57%)
VIG : 98.13 (-0.31%)
PEP : 115.08 (-0.84%)
CME : 141.87 (-0.50%)
SKT : 24.40 (+1.08%)
DWDP : 70.60 (-0.93%)
J&J Seeks Darzalex's Label Expansion in First-Line Setting

Johnson & Johnson (JNJ) has submitted regulatory applications in the United States and EU for label expansion of Darzalex as first-line therapy for multiple myeloma.

CELG : 105.16 (+0.63%)
JNJ : 137.29 (-0.76%)
AMGN : 169.96 (+0.07%)
BMY : 61.14 (-0.16%)
JP Morgan Launches US Dividend ETF

JP Morgan rolls out multi-cap US Dividend ETF.

HFC : 44.39 (-0.89%)
JDIV : 25.11 (unch)
DVY : 95.61 (-0.01%)
JNJ : 137.29 (-0.76%)
SDY : 93.59 (+0.05%)
DLR : 117.21 (-0.90%)
MCD : 169.05 (+0.45%)
NNN : 42.55 (-0.26%)
MSFT : 83.11 (-0.73%)
LMT : 314.87 (-0.65%)
T : 34.87 (+1.57%)
VIG : 98.13 (-0.31%)
PEP : 115.08 (-0.84%)
CME : 141.87 (-0.50%)
SKT : 24.40 (+1.08%)
DWDP : 70.60 (-0.93%)
J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen

J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.

JNJ : 137.29 (-0.76%)
GILD : 72.82 (+0.43%)
PFE : 35.43 (-0.31%)
GSK : 35.06 (+0.72%)
New Data Demonstrates >90% Year 1 Success Rate for Radiofrequency Ablation in Treating Patients with Atrial Fibrillation

Published data from the Journal of American College of Cardiology: Clinical Electrophysiology showcased at the 15th edition of Venice Arrhythmias 2017

JNJ : 137.29 (-0.76%)
Quality Dividend ETFs to Tackle Uncertainty

Consider these 3 dividend ETFs for your portfolio to fight growing market uncertainty.

MSFT : 83.11 (-0.73%)
AAPL : 174.96 (+1.05%)
QDF : 43.36 (-0.12%)
WFC : 54.06 (-0.84%)
INTC : 44.65 (-0.65%)
JNJ : 137.29 (-0.76%)
DGRW : 39.82 (-0.10%)
SCHD : 49.20 (-0.22%)
HD : 172.06 (-0.46%)
BA : 265.15 (-0.69%)
Quality Dividend ETFs to Tackle Uncertainty

Consider these 3 dividend ETFs for your portfolio to fight growing market uncertainty.

MSFT : 83.11 (-0.73%)
AAPL : 174.96 (+1.05%)
QDF : 43.36 (-0.12%)
WFC : 54.06 (-0.84%)
INTC : 44.65 (-0.65%)
JNJ : 137.29 (-0.76%)
DGRW : 39.82 (-0.10%)
SCHD : 49.20 (-0.22%)
HD : 172.06 (-0.46%)
BA : 265.15 (-0.69%)
United Therapeutics PAH Drug's Exclusivity Period Extended

United Therapeutics' PAH drug, Adcirca has been granted six months pediatric exclusivity. This will delay generic competition for the drug for an additional six months.

JNJ : 137.29 (-0.76%)
LLY : 83.68 (+0.20%)
GILD : 72.82 (+0.43%)
UTHR : 125.41 (unch)
Risperdal Gynecomastia Lawsuit Headed for New Trial After Pennsylvania Superior Court Overturns Defense Verdict, Bernstein Liebhard LLP Reports

A Plaintiff who claims to have developed gynecomastia due to his use of Risperdal will get a new trial, after a three-judge panel of the Pennsylvania Superior Court reversed the only verdict favoring Johnson...

JNJ : 137.29 (-0.76%)
Global Intraocular Lenses Strategic Market 2016-2024 - Leading Players are Alcon, Bausch & Lomb, Johnson & Johnson Vision Care, Zeiss

The "Intraocular Lenses - Global Strategic Business Report" report has been added to Research and Markets' offering.

JNJ : 137.29 (-0.76%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 139.20
1st Resistance Point 138.25
Last Price 137.29
1st Support Level 136.47
2nd Support Level 135.64

See More

52-Week High 144.35
Last Price 137.29
Fibonacci 61.8% 130.97
Fibonacci 50% 126.84
Fibonacci 38.2% 122.70
52-Week Low 109.32

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart